Between the rarity of a securities fraud case going to trial, attorneys dropping at the last minute and investors alleging they were defrauded of millions, the April bench trial against the former CEO of a pharmaceutical packaging company would have been noteworthy in any year.
But with the case the first to go before a Delaware federal court in person since the pandemic began and the parties having just a few weeks between the trial being confirmed and opening statements, Cozen O’Connor attorneys are considering U.S. District Judge Richard G. Andrews’ awarding of both investment losses and punitive damages this week an especially significant win.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]